The Global Race to Secure API Manufacturing: Lessons from Recent Shortages

Sponsored content: this article was produced by a third-party contributor and does not reflect the views of The Industry Leaders. Editorial & Advertising Policy.

The global pharmaceutical industry learned an uncomfortable lesson between 2022 and 2025. Drug shortages aren't caused by bad luck. They're caused by structural weaknesses in how and where active pharmaceutical ingredients are made.

Adderall shortages that began in late 2022 stretched into 2024, affecting millions of ADHD patients. Semaglutide injection supply was constrained for over two years before the FDA declared the shortage resolved in February 2025. Chemotherapy drugs, antibiotics, and generic psychiatric medications all appeared on the FDA's shortage list at various points, sometimes for months at a time.

In each case, the root cause traced back to the same place: api manufacturing capacity that was too concentrated, too fragile, or too slow to respond to demand shifts. What's happening now is a global race to fix those vulnerabilities before the next disruption hits.

How API Manufacturing Became a Single Point of Failure

The concentration of api manufacturing in a small number of countries and facilities didn't happen overnight. It was the result of decades of cost optimization.

As generic drug pricing compressed through the 2000s and 2010s, manufacturers in higher-cost geographies exited product lines that no longer justified the investment. Production consolidated in India and China, where lower labor costs, established chemical supply chains, and less expensive regulatory compliance environments made manufacturing economically viable at thin margins.

The FDA's drug shortage database documents the consequences. Manufacturing-related causes, including quality failures, facility shutdowns, and raw material disruptions, consistently rank as the top drivers of drug shortages. When only two or three facilities globally produce a given API, any single disruption creates a supply gap that can take months to close.

For companies looking to build resilience into their supply chains, working with partners that offer diversified api manufacturing services across multiple qualified facilities has become a strategic priority rather than a procurement preference.

India illustrates both sides of this equation. The country supplies approximately 20% of the world's generic medicines by volume, making it indispensable to global drug access. But Indian api manufacturing depends on China for roughly 70% of its pharmaceutical intermediates and key starting materials. A disruption at the intermediate level cascades into finished API supply within weeks.

What Recent Shortages Actually Revealed

Each major shortage of the past three years exposed a different structural weakness, but the pattern across all of them was consistent.

The semaglutide shortage

It wasn't caused by manufacturing failure. It was caused by demand growing faster than api manufacturing capacity could expand. Novo Nordisk and its contract partners simply couldn't build peptide synthesis and purification infrastructure fast enough to keep up with prescribing volume that multiplied year over year. The shortage demonstrated that even well-run manufacturing operations become bottlenecks when a drug's commercial success outpaces the industry's ability to produce it.

Generic SSRI and ADHD medication shortages

It resulted from the opposite problem. Margins on these high-volume generics had compressed to the point where manufacturers exited product lines. When remaining producers encountered quality issues or regulatory actions, there wasn't enough backup capacity in the system to compensate. The api manufacturing base for these essential medicines had been hollowed out by economics.

Chemotherapy drug shortages

Particularly for generic injectable oncology APIs, it followed a similar pattern. Production concentrated in a handful of facilities, and when one received a warning letter or import alert, the supply gap persisted until remediation was complete, sometimes leaving oncologists without access to standard-of-care treatments for months.

How Governments and Industry Are Responding

The recognition that api manufacturing concentration creates national security risk has triggered policy responses across multiple countries simultaneously.

In the United States, the BIOSECURE Act signed in December 2025 restricts government contracts with entities linked to certain Chinese biotechnology companies, with a wind-down deadline of 2032. The FDA's "Green List" system now enables detention of APIs from unverified foreign manufacturers without physical inspection. Trade tariffs on pharmaceutical imports, proposed as high as 250%, have added further cost uncertainty to overseas sourcing.

The European Union has accelerated its Critical Medicines Act, which aims to reduce dependency on non-EU api manufacturing sources for essential drugs. Several member states are offering incentives for domestic pharmaceutical production capacity.

India has expanded its Production Linked Incentive scheme for pharmaceutical manufacturing, directing subsidies toward api manufacturing for molecules where domestic self-sufficiency is a strategic priority.

The common thread across all these responses is a shift from cost-optimized sourcing toward resilience-optimized sourcing. Governments have concluded that the cheapest API supply chain is not necessarily the safest one.

What's Actually Changing on the Ground

Policy signals are important, but what matters for drug supply is whether physical api manufacturing capacity is actually being built.

The evidence suggests it is, though unevenly. Total disclosed CDMO investment reached $24.86 billion in 2025, with 74% flowing to US facilities, partly in response to the BIOSECURE Act. Peptide api manufacturing has seen particularly aggressive expansion, with CordenPharma committing €900 million to peptide platform capacity and multiple other CDMOs announcing new or expanded facilities.

But building a qualified GMP facility takes three to five years. Validating it for commercial production adds more time. The capacity being announced today won't come online until 2028 or 2029 at the earliest. In the interim, the same concentration risks that caused recent shortages remain largely unresolved.

Dual sourcing strategies are filling part of the gap. Companies that previously relied on single suppliers are qualifying backup manufacturers in different geographies. This creates redundancy at the individual company level, even if the systemic concentration problem persists at the industry level.

What Still Needs to Change

Building new facilities addresses capacity. It doesn't address the economic dynamics that caused concentration in the first place.

As long as generic api manufacturing operates on margins too thin to sustain redundant capacity, the supplier base will remain fragile. A facility that runs one essential API at breakeven won't invest in backup production lines or maintain excess inventory. When that facility goes offline, patients bear the consequences.

Solving this requires structural changes to how essential medicines are valued by health systems. Strategic stockpile programs, minimum manufacturing diversity requirements for essential drugs, and pricing models that reflect true supply chain costs rather than race-to-the-bottom procurement are all being discussed. Whether they get implemented at the scale needed remains an open question.

Where Neuland Laboratories Fits

Neuland Laboratories operates three cGMP-certified api manufacturing facilities in India with over 400 R&D scientists and regulatory approvals from the FDA, EMA, and PMDA.

Their capabilities span complex small molecules, peptides, and high-potency APIs, with a multi-site infrastructure designed to provide the manufacturing redundancy and geographic diversification that modern pharmaceutical supply chains demand.

FAQs

1. Why can't drug companies simply build more API manufacturing plants to prevent shortages?

Building a GMP-qualified facility costs $200 million or more and takes three to five years from groundbreaking to validated commercial production. For generic APIs with thin margins, the return on that investment often doesn't justify the capital. Companies build capacity where the economics support it, which is why expansion tends to follow high-value molecules like peptides rather than low-margin generics where shortages are most frequent.

2. How does the BIOSECURE Act affect global API supply chains?

The Act restricts US government contracts with entities linked to specific Chinese biotechnology companies, with a 2032 compliance deadline. The practical effect is accelerating supply chain diversification:

• Companies are qualifying alternative manufacturers in India, Europe, and the US

• CDMO investment is shifting geographically, with 74% of 2025 disclosed investment flowing to US facilities

• Long-term contracts with non-restricted partners are increasing in value and duration

The transition will take years, and interim supply disruptions remain a risk during the changeover period.

3. Are strategic stockpiles of APIs an effective solution to drug shortages?

Stockpiles help for short-term disruptions but aren't a permanent fix. APIs have finite shelf lives, typically two to five years, which means stockpiled material must be rotated and replaced continuously. The cost of maintaining a national pharmaceutical reserve is significant, and stockpiles don't address the underlying manufacturing concentration that causes shortages in the first place. They buy time, but they don't solve the structural problem.

4. Which types of drugs are most vulnerable to API manufacturing disruptions?

High-volume generic drugs with few remaining manufacturers carry the highest shortage risk. Injectable oncology drugs, generic antibiotics, and psychiatric medications have all experienced extended shortages in recent years. The common factors are compressed margins that discourage investment in backup capacity, concentrated production in a small number of facilities, and limited ability to substitute alternative treatments when supply gaps occur.